Search

Displaying results 1451 - 1460 of 8517 in total
  1. Drug

    Nesiritide

    go.drugbank.com/drugs/DB04899
    ApprovedInvestigationalWithdrawn

    Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing).

  2. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    [A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695] … [A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.

    Synonyms: (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
  3. Drug

    Isatuximab

    go.drugbank.com/drugs/DB14811
    ApprovedInvestigational

    Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was

  4. Drug

    Isotretinoin

    go.drugbank.com/drugs/DB00982
    ApprovedInvestigational

    [Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. … [L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]

  5. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … [L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967. It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.

  6. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. … [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925]

  7. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].

  8. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    It was first described in 1998 at the Pierre Fabre research center in France. … In 2009, vinflunine was approved by the European Medicines Agency (EMA) as a second-line therapy of metastatic and advanced urothelial cancer after failure of platinum-based treatment [A32626].

  9. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin

  10. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission